MELISSA MATZEK: Open Payments
NPI 1932868809 · SHAWNEE MISSION, KS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$854 in 72 payments from 15 companies in 2025. Trend: 2023 $1,739 · 2024 $2,854 · 2025 $854
Food & beverage: $854
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 54 | $510 |
| ARGENX US, INC. | 2 | $51 |
| Celgene Corporation | 2 | $34 |
| Novartis Pharmaceuticals Corporation | 2 | $33 |
| JAZZ PHARMACEUTICALS INC. | 2 | $29 |
| Neurelis, Inc. | 1 | $26 |
| Genentech USA, Inc. | 1 | $24 |
| Axsome Therapeutics, Inc. | 1 | $21 |
| Grifols USA, LLC | 1 | $21 |
| Vanda Pharmaceuticals Inc. | 1 | $21 |
Products named: QULIPTA, UBRELVY, VYVGART HYTRULO, ZEPOSIA, KESIMPTA, EPIDIOLEX, VALTOCO, Ocrevus Zunovo.
Industry payments across KS — which companies pay providers there.
